Rigel Pharmaceuticals | RIGL - Operating Expenses


Rigel Pharmaceuticals reported $117.61M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Agenus USD -199.08M 22.15M Jun/2026
Amgen USD 11.69B 6.9B Jun/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 245.35M 30.35M Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
BioMarin Pharmaceutical USD 6.32B 5.69B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Celldex Therapeutics USD 714.56M 258.34M Jun/2026
Daiichi Sankyo JPY 489.64B 21.08B Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
Halozyme Therapeutics USD 193.34M 1.15M Jun/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Intrexon USD 61.56M 26.1M Jun/2024
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Ligand Pharmaceuticals USD 55.1M 20.75M Jun/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Veracyte USD 126.36M 6.37M Jun/2026